

2011 SABCS Disclosure Report

Program #	Title	F. Name	L.Name	Disclosure Information
Educational Session "Controversies in Early Breast Cancer" Speaker/Committee Member	Chemotherapy benefit in ER positive breast cancer — Mixed messages	Kathy	Albain	Dr. Albain has disclosed that she is a consultant/advisor for Genomic Health, Inc., Genentech and ENZON. She has also disclosed she is a meeting participant/lecturer for Genomic Health, Inc. Dr. Albain has disclosed she does scientific study/trial for Merck Oncology and ISMC for Pfizer trials as chair member.
Committee Member	N/A	D Craig	Allred	Dr. Allred has no relevant financial relationships to disclose.
Educational Session Moderator//Mini-Symposia "The Role and Promise of Neoadjuvant Therapy in Breast Cancer" Speaker/Committee Member/Brinker Award Speaker	Mouse Models of PI3K-Dependent and Basal-Like Breast Cancer/Neoadjuvant trials as a discovery tool/Oncogenes & ER: A convenient marriage for hormone-dependent breast cancer	Carlos	Arteaga	Dr. Arteaga has no relevant financial relationships to disclose.
General Session 3 Moderator/Committee Member	N/A	Jose	Baselga	Dr. Baselga has disclosed that he is a consultant/advisor for Exelixis, Sanofi, Novartis and Chugai.
Educational Session "New Technologies for Biomarker Discovery for the Clinician" Speaker	The potential of epigenetic therapy in breast cancer	Stephen	Baylin	Dr. Baylin has disclosed that his is a consultant/advisor for BioNumerick Pharm, MDxHealth, Constellation Pharm and Astex Pharm.
Case Discussion 2 Panelist	N/A	Jennifer	Bellon	Dr. Bellon has no relevant financial relationships to disclose.
Mini-Symposia "Tumor Heterogeneity and Metastasis" Speaker	Tumor-entrained neutrophils inhibit breast cancer metastasis seeding in the lung	Robert	Benezra	Dr. Benezra has no relevant financial relationships to disclose.
Case Discussion 1 Panelist	N/A	John	Benson	Dr. Benson has disclosed that he is a consultant/advisor for Merrimack Pharmaceuticals.
Committee Member	N/A	Christopher	Benz	Dr. Benz has disclosed that he is a consultant/advisor for Merrimack Pharmaceuticals.
Case Discussion 2 Panelist/Committee Member	N/A	Kimberly	Blackwell	Dr. Blackwell has disclosed that she is a consultant/advisor for GSK and Genentech. She has also disclosed she is on the speaker's bureau for Sanofi-Aventis, Novartis, BMS, Genomic Health and GSK.
Committee Member	N/A	Melissa	Bondy	Dr. Bondy has no relevant financial relationships to disclose.
Special Reports "Genome Data for the Masses: Presentation of TCGA and IGC Breast Tumor Data" Speaker	The DNA copy number landscapes and genomic architecture: Relevance for progression and outcome	Anne-Lise	Børresen-Dale	Dr. Børresen-Dale has no relevant financial relationships to disclose.
Case Discussion 2 Panelist	N/A	Vernal	Branch	Ms. Branch has disclosed she is a consultant/advisor for Duke and CBCRP. She has also disclosed is an investigator and does scientific study/trials for UVA. Ms. Branch has disclosed she is a meeting participant/lecturer for NBCC Advocacy Conf and DOD Era of Hope.

2011 SABCS Disclosure Report

Program #	Title	F. Name	L.Name	Disclosure Information
Basic Science Forum "Estrogen Receptor" Speaker	Steroid receptor cistromics	Myles A.	Brown	Dr. Brown has disclosed he is a consultant/advisor for Novartis and Pfizer.
Committee Member	N/A	Powel	Brown	Dr. Brown has disclosed he is a scientific advisory board member for Susan G. Komen for the Cure.
Committee Member	N/A	Susan E.	Brown	Ms. Brown has no relevant financial relationships to disclose.
AACR Distinguished Lectureship in Breast Cancer Research Speaker	Protective Adaptive Responses to Breast Cancer Therapies	Joan S.	Brugge	Dr. Brugge has disclosed that she is a consultant/advisor for Novartis Option Fund, Millennium Takeda and Johnson & Johnson.
Mini-Symposia "The Role and Promise of Neoadjuvant Therapy in Breast Cancer" Speaker	Interface with radiation oncology	Thomas A.	Buchholz	Dr. Buchholz has no relevant financial relationships to disclose.
Mini-Symposia "The Role and Promise of Neoadjuvant Therapy in Breast Cancer" Moderator and Speaker/Case Discussion 1 Panelist/Committee Member	The Neoadjuvant Setting, HER2-Driven and Triple Negative Breast Cancer	Lisa A.	Carey	Dr. Carey has no relevant financial relationships to disclose.
Committee Member	N/A	Gary C.	Chamness	Dr. Chamness has no relevant financial relationships to disclose.
Committee Member	N/A	Eric	Chang	Dr. Chang has no relevant financial relationships to disclose.
Committee Member	N/A	Rowan	Chlebowski	Dr. Chlebowski has disclosed that he is a consultant/advisor for Novartis, Astra-Zeneca, Genomic Health, Amgen and Celgene. He has also disclosed that he does scientific study/trial for Amgen.
Educational Session "Reconstruction" Speaker	Breast reconstruction with implants and post-mastectomy irradiation: algorithms and outcomes	Peter G.	Cordeiro	Dr. Cordeiro has disclosed that he does scientific study/trial for Allergan Corporation.
Plenary Speaker	Macrophages as Novel Targets for Therapy in Breast Cancer	Lisa M.	Coussens	Dr. Coussens has no relevant financial relationships to disclose.
Special Reports "Genome Data for the Masses: Presentation of TCGA and IGC Breast Tumor Data" Speaker	Integrative genomic analyses of breast cancer from The Cancer Genome Atlas (TCGA)	Chad J.	Creighton	Dr. Creighton has no relevant financial relationships to disclose.
Committee Member	N/A	Massimo	Cristofanilli	Dr. Cristofanilli has disclosed that he is a consultant/advisor for Dompe and Alere.
Educational Session Moderator/Committee Member/Poster Discussion 2 Discussant	Reconstruction	Richard L.	Crownover	Dr. Crownover has no relevant financial relationships to disclose.
The Year in Review Speaker	Early Breast Cancer	Nancy E.	Davidson	Dr. Davidson has no relevant financial relationships to disclose.

2011 SABCS Disclosure Report

Program #	Title	F. Name	L.Name	Disclosure Information
Educational Session "Controversies in Early Breast Cancer" Speaker	Adjuvant therapy in patients with a borderline HER-2 status	Angelo	Di Leo	Dr. Di Leo has disclosed that he is a consultant/advisor and a meeting participant/lecturer for AZ, Cephalon, GSK, Pfizer, Roche and Sanofi-Aventis. He has also disclosed he does scientific study/trial for AZ and GSK.
Committee Member	N/A	Mitchell	Dowsett	Dr. Dowsett has disclosed that he is a consultant for Roche, HRA, Genoptix and Sanofi. He has also disclosed he is an investigator for Novartis, Astra-Zeneca and Pfizer. Dr. Dowsett has disclosed he is a meeting participant/lecturer for Roche and Astra-Zeneca. He has also disclosed he does scientific study/trial for Pfizer and Astra-Zeneca.
Clinical Science Forum "Medical Economics – The Cost of Care" Speaker	The cost of cancer care: How much do we spend and how can we spend it better?	Elena	Elkin	Dr. Elkin has no relevant financial relationships to disclose.
Mini-Symposia "Tumor Heterogeneity and Metastasis" Speaker	Tumor heterogeneity and metastasis	Matthew J.	Ellis	Dr. Ellis has no relevant financial relationships to disclose.
General Session 4 Moderator	N/A	Rutgers	Emiel J T	Dr. Rutgers has no relevant financial relationships to disclose.
Committee Member	N/A	Carol	Fabian	Dr. Fabian has no relevant financial relationships to disclose.
Educational Session "What Makes a Good Target?" Moderator and Speaker	Target, identification and drug discovery: What is druggable?	Stephen W.	Fesik	Dr. Fesik has no relevant financial relationships to disclose.
Mini-Symposia "Environmental Exposures, Epigenetics, and Epidemiology" Speaker	Epidemiology of preeclampsia and other early exposures on breast cancer risk	Michele R.	Forman	Dr. Forman has no relevant financial relationships to disclose.
Committee Member	N/A	Margaret	Foti	Dr. Foti has no relevant financial relationships to disclose.
Mini-Symposia "Tumor Heterogeneity and Metastasis" Speaker	Imaging cancer invasion and experimental therapy response: How to overcome resistance niches	Peter	Friedl	Dr. Friedl has no relevant financial relationships to disclose.
Basic Science Forum Moderator/Committee Member	Estrogen Receptor	Suzanne A.W.	Fuqua	Dr. Fuqua has no relevant financial relationships to disclose.
General Session 6 Discussant	N/A	Patricia	Ganz	Dr. Ganz has no relevant financial relationships to disclose.
Committee Member/Poster Discussion 1 Discussant	N/A	Judy E.	Garber	Dr. Garber has disclosed that she is a consultant/advisor for spouse consults for Novartis. She has also disclosed she does scientific study/trial for Abbott Pharmaceuticals.
Committee Member	N/A	Luca	Gianni	Dr. Gianni has disclosed that he is a consultant/advisor for Roche, Millennium, Eisai, Biogen, Sanofi-Aventis, and Novartis.
Brinker Award Speaker	Changes in the Management of the Axilla in Breast Cancer	Armando E.	Giuliano	Dr. Giuliano has no relevant financial relationships to disclose.

2011 SABCS Disclosure Report

Program #	Title	F. Name	L.Name	Disclosure Information
Committee Member	N/A	Stefan	Gluck	Dr. Gluck has disclosed that he is a consultant/advisor, an investigator, a meeting participant/lecturer and does scientific study/trial for Agendia, Eisai, Genentech, GSK and Celgene.
Committee Member	N/A	Matthew	Goetz	Dr. Goetz has no relevant financial relationships to disclose.
Committee Member/Poster Discussion 9 Discussant	N/A	Ana Maria	Gonzalez-Angulo	Dr. Gonzalez-Angulo has no relevant financial relationships to disclose.
General Session 6 Moderator	N/A	Pamela	Goodwin	Dr. Goodwin has no relevant financial relationships to disclose.
Committee Member	N/A	Paul	Goss	Dr. Goss has disclosed that he is an employee of Massachusetts General Hospital. He has also disclosed he is a meeting participant/lecturer for Pfizer. Dr. Goss has disclosed that he does scientific study/trial for GSK, Pfizer and Amgen (clinical trials).
Committee Member	N/A	Stephen	Gottschalk	Dr. Gottschalk has no relevant financial relationships to disclose.
General Session 2 Moderator	N/A	Julie R.	Gralow	Dr. Gralow has disclosed that she receives research funding from Amgen, Novartis, Roche, Genentech and Sanofi Aventis.
William L. McGuire Memorial Lecture/Committee Member	Translation Genomic Insights into Improved Breast Cancer Management	Joe	Gray	Dr. Gray has disclosed that he is a board member/officer/trustee for New Leaf Ventures, Kroma TiD and Susan G. Komen for the Cure. He has also disclosed that he is consultant/advisor for New Leaf. Dr. Gray has disclosed that he received grant/support from Glaxo Smith Kline, Roche, Millennium, Pfizer and Susan G. Komen for the Cure.
Educational Session "Breast Cancer Trials in Developing Countries – Opportunities and Challenges" Speaker	Challenges in the design and implementation of breast cancer clinical trials in developing countries	Sudeep	Gupta	Dr. Gupta has disclosed that he is a consultant/advisor for Roche, GSK, Sanofi-Aventis and BMS. He has also disclosed that he is a meeting participant/lecturer for Sanofi-Aventis and BMS.
Committee Member	N/A	M. Carolina	Gutierrez	Dr. Gutierrez has no relevant financial relationships to disclose.
Mini-Symposia "Metabolism in Breast Cancer – Metabolomics" speaker	Adiposity, metabolism, and risk of breast cancer	Susan E.	Hankinson	Dr. Hankinson has no relevant financial relationships to disclose.
Committee Member	N/A	Jay	Harris	Dr. Harris has no relevant financial relationships to disclose.

2011 SABCS Disclosure Report

Program #	Title	F. Name	L.Name	Disclosure Information
Clinical Science Forum "Medical Economics – The Cost of Care" Speaker	Health care reform and cost control: Practical and ethical considerations for cancer care providers	Michael	Hassett	Dr. Hassett has no relevant financial relationships to disclose.
Special Reports "Genome Data for the Masses: Presentation of TCGA and IGC Breast Tumor Data" Speaker	Genomic analyzes for pathway characterization	David	Haussler	Dr. Haussler has disclosed that he is a consultant/advisor for five3 genomics and Pacific Biosciences. He has also disclosed that he is an employee with University of California, Santa Cruz and Howard Hughes Medical Institute. Dr. Haussler has disclosed he is an investigator for Howard Hughes Medical Institute. He has also disclosed he does scientific study/trial for ISPY-1 and ISPY-2.
Case Discussion 1 Panelist/Committee Member	N/A	Daniel	Hayes	Dr. Hayes has disclosed that he is a consultant/advisor for Chugai Pharmaceuticals and Biomarker Strategies. He has also disclosed he is an investigator for Pfizer, Novartis and Veridex (Johnson & Johnson). Dr. Hayes has an investment interest in Oncimmune LLC.
Committee Member/Poster Discussion 4 Discussant	N/A	Dawn	Hershman	Dr. Hershman has no relevant financial relationships to disclose.
Special Reports Speaker	Breast Cancer and the Environment: A Life Course Approach -- Report Release from an IOM Committee	Irva	Hertz-Picciotto	Dr. Hertz-Picciotto has no relevant financial relationships to disclose.
Special Reports Speaker/Mini-Symposium "Environmental Exposures, Epigenetics, and Epidemiology" Speaker	Breast Cancer and the Environment: A Life Course Approach -- Report Release from an IOM Committee /Environ exposures, epigenetics & epidemiology influence of environmental factors on pubertal maturation and breast cancer etiology	Robert A.	Hiatt	Dr. Hiatt has no relevant financial relationships to disclose.
Committee Member	N/A	Bruce	Hillner	Dr. Hillner has no relevant financial relationships to disclose.
Committee Member	N/A	Susan G.	Hilsenbeck	Dr. Hilsenbeck has no relevant financial relationships to disclose.
Educational Session "Breast Cancer Trials in Developing Countries – Opportunities and Challenges" Speaker	Practicality, promise and pitfalls in industry-sponsored trials (in developing countries)	Sandra J.	Horning	Dr. Horning has no relevant financial relationships to disclose.
Committee Member	N/A	Gabriel	Hortobagyi	Dr. Hortobagyi had disclosed that he is a consultant/advisor for Genentech, Allergan, Sanofi and Novartis. He has also disclosed he does scientific study/trial for Novartis.
Committee Member	N/A	Tim Hui-Ming	Huang	Dr. Huang has no relevant financial relationships to disclose.
Committee Member/Poster Discussion 7 Discussant	N/A	Clifford	Hudis	Dr. Hudis has disclosed that he is an investigator for Onyx Pharmaceutical and Merck (to institution).

2011 SABCS Disclosure Report

Program #	Title	F. Name	L.Name	Disclosure Information
Committee Member	N/A	Kelly	Hunt	Dr. Hunt has no relevant financial relationships to disclose.
Educational Session "Challenges in the Care of Special Populations with Breast Cancer" Speaker	Treatment of older women with breast cancer	Arti	Hurria	Dr. Hurria has disclosed that he is a consultant/advisor for GTX. He has also disclosed he does scientific study/trial for Abraxis Bioscience (n.w Celgene) and GSK.
General Session 1 Discussant/Committee Member	N/A	James	Ingle	Dr. Ingle has disclosed that he is a consultant/advisor for Pfizer: Academic Steering Committee-Extenet Trial (uncompensated).
Educational Session Moderator/Committee Member/Poster Discussion 2 Discussant/Case Discussion 2 Panelist	Breast Cancer Trials in Developing Countries - Opportunities and Challenges	Ismail	Jatoi	Dr. Jatoi has no relevant financial relationships to disclose.
Committee Member	N/A	Maria	Jibaja-Weiss	Dr. Jibaja-Weiss has no relevant financial relationships to disclose.
Educational Session "Mouse Models of PI3K-Dependent and Basal-Like Breast Cancer" Speaker	Mouse models of basal-like breast cancer	Jos	Jonkers	Dr. Jonkers has no relevant financial relationships to disclose.
Educational Session "Breast Cancer Trials in Developing Countries – Opportunities and Challenges" Speaker	Novel approach to breast cancer in low income countries	David J.	Kerr	Dr. Kerr has disclosed that he is a consultant/advisor for Genomic Health. He has also disclosed that he is an investigator for Roche. Dr. Kerr is a meeting participant/lecturer for Genomic Health.
Committee Member	N/A	Seema	Khan	Dr. Khan has no relevant financial relationships to disclose.
Committee Member	N/A	Tari	King	Dr. King has no relevant financial relationships to disclose.
Educational Session "Treatment of Metastatic Breast Cancer – Breast Cancer as a Chronic Disease" Speaker	HER2 positive	Ian E.	Krop	Dr. Krop has disclosed that his a consultant/advisor for Novartis. He has also disclosed that he is an investigator for Genentech and Roche.
Committee Member	N/A	Rakesh F	Kumar	Dr. Kumar has no relevant financial relationships to disclose.
Committee Member	N/A	Charlotte	Kuperwasser	Dr. Kuperwasser has no relevant financial relationships to disclose.
Special Reports "Genome Data for the Masses: Presentation of TCGA and IGC Breast Tumor Data" Speaker	Epigenomic data analysis of TCGA breast cancer samples	Peter W.	Laird	Dr. Laird has disclosed that he is a board member/officer/trustee and a consultant/advisor for Epigenomics, AG.
Committee Member	N/A	Adrian	Lee	Dr. Lee has disclosed that he does scientific study/trials for Bristol Meyers Squibb.
Educational Session "Mouse Models of PI3K-Dependent and Basal-Like Breast Cancer" Speaker/Committee Member	Patient-derived xenograft models for preclinical breast cancer research: Not just "basal" anymore	Michael	Lewis	Dr. Lewis has disclosed that she has investment interest with Limited partner, SternMed LP.
Basic Science Forum Moderator/Committee Member	Tumor Microenvironment	Rong	Li	Dr. Li has no relevant financial relationships to disclose.
Basic Science Forum Moderator/Committee Member	Tumor Initiation	Yi	Li	Dr. Li has no relevant financial relationships to disclose.
Poster Discussion 8 Discussant	N/A	Geoffrey	Lindeman	Dr. Lindeman has disclosed that he is a consultant/advisor for Sanofi-Aventis.

2011 SABCS Disclosure Report

Program #	Title	F. Name	L. Name	Disclosure Information
Committee Member	N/A	Jafi	Lipson	Dr. Lipson has no relevant financial relationships to disclose.
Committee Member	N/A	Anthony	Lucci	Dr. Lucci has no relevant financial relationships to disclose.
Committee Member	N/A	David A.	Mankoff	Dr. Mankoff has disclosed that he does scientific study/trial for Merck and Pfizer.
Special Reports "Genome Data for the Masses: Presentation of TCGA and IGC Breast Tumor Data" Speaker	TCGA breast cancer sequencing: Results and interpretation	Elaine R.	Mardis	Dr. Mardis has disclosed that she is a consultant/advisor for Biomarin Pharmaceuticals.
General Session 1 Moderator/Committee Member	N/A	Kathy	Miller	Dr. Miller has disclosed that she is a consultant/advisor for Genentech/Roche, BMS and AstraZeneca. She has also disclosed she does scientific study/trial for Institutional support for ongoing clinical research provided by Genentech/Roche, Pfizer, Geron, Merrimack and Sundax.
Educational Session "New Technologies for Biomarker Discovery for the Clinician" Speaker	Proteomics	Gordon	Mills	Dr. Mills has disclosed that he is a consultant for Ambit, Amira, Affymetrix, Arcxis, Biotechnologies, AstraZeneca, Aushon BioSystems, Catena, Celgene, Daiichi Sankyo, DeltaDot, Enzon, GSK, LPATH, PTV, Ventures, Semafore, Tau, Wyeth and Foundation Medicine. He has also disclosed he has stock options with Arcxis, Catena, Semafore, LPATH and PTV. Dr. Mills has disclosed he sponsors research for Affymetrix, AstraZeneca, Celgene, CeMines, Exelixis, GSK, Keryz, LPATH, Myriad, SDI, Semafore, Sequenom and Wyeth/Pfizer.
Committee Member	N/A	Mark	Moasser	Dr. Moasser has disclosed that she is a consultant/advisor for Myriad Genetics, Merrimack Pharmaceuticals.
Committee Member	N/A	Susan	Mooberry	Dr. Mooberry has disclosed that she is a consultant/advisor for Eisai Pharmaceuticals
Committee Member	N/A	Pamela	Munster	Dr. Munster has no relevant financial relationships to disclose.
Basic Science Forum "Estrogen Receptor" Speaker	Nuclear receptor coactivators: Physiology and disease	Bert W.	O'Malley	Dr. O'Malley has no relevant financial relationships to disclose.
The Year in Review Moderator/Committee Member/General Session 5 Discussant	N/A	C. Kent	Osborne	Dr. Osborne had disclosed that he is a consultant/advisor for AstraZeneca.
Committee Member	N/A	Soon-Myung	Paik	Dr. Paik has disclosed that he does scientific study/trial for GSK, Roche/Genentech, Pfizer, Eisai and Astra Zeneca.
Committee Member	N/A	Klaus	Pantel	Dr. Pantel has no relevant financial relationships to disclose.
Educational Session "Mouse Models of PI3K-Dependent and Basal-Like Breast Cancer" Speaker/AACR Distinguished Lecture in Breast Cancer Research Speaker	PI3K mouse models of breast cancer/Alteration and Inhibition of PTEN in Breast Cancer	Ramon	Parsons	Dr. Parsons has no relevant financial relationships to disclose.

2011 SABCS Disclosure Report

Program #	Title	F. Name	L.Name	Disclosure Information
Educational Session "Challenges in the Care of Special Populations with Breast Cancer" Speaker	Treatment of young women with breast cancer	Ann H.	Partridge	Dr. Partridge has no relevant financial relationships to disclose.
Educational Session "What Makes a Good Target?" Moderator and Speaker	Clinical validation of new therapeutic targets in breast cancer	Mark	Pegram	Dr. Pegram has no relevant financial relationships to disclose.
Committee Member	N/A	Edith	Perez	Dr. Perez has no relevant financial relationships to disclose.
Special Reports Co-Moderator/Committee Member	Genome Data for the Masses: Presentation of TCGA and IGC Breast Tumor Data	Charles M.	Perou	Dr. Perou has disclosed that he is a consultant/advisor for Roche and AstraZeneca. He has also disclosed that he has investment interest with University Genomics and Bioclassifier, LLC. Dr. Perou has disclosed that he does scientific study/trial for Roche.
Case Discussion 2 Panelist/Committee Member	N/A	Martine	Piccart	Dr. Piccart has disclosed that she is a board member for PharmaDar. She has also disclosed that she is a consultant/advisor for Roche, Boehringer, Celgene, Sanofi-Aventis. Dr. Piccart has disclosed that she is an investigator for Alto, Dindact, Bolerog, Lux-Breast 1 Trial. She has also disclosed that she is a meeting participant/lecturer for Prime Oncology, GSK, Novartis, AZ and Roche.
Committee Member	N/A	Lori	Pierce	Dr. Pierce has no relevant financial relationships to disclose.
Mini-Symposia "Metabolism in Breast Cancer – Metabolomics" Speaker and Moderator	Energy metabolism in breast cancer: Translational science insights relevant to effects of diet, exercise, and metformin on risk and prognosis	Michael	Pollak	Dr. Pollak has disclosed that he is a consultant/advisor for Pfizer, Bristol Myers Squibb, Boehringer Ingelheim and Novo Nordisk. He has also disclosed that he does scientific study/trial for Pfizer. Dr. Pollak has disclosed he receives research support from Novo Nordisk.
The Year in Review Speaker	Advances in Basic Breast Cancer Research	Kornelia	Polyak	Dr. Polyak has disclosed that she is board member/officer/trustee for Metamark Genetics, Inc. and Theracrine, Inc. She has also disclosed that she is a consultant/advisor for Novartis Oncology. Dr. Polyak has disclosed that she has investment interest with Aveo Pharmaceuticals, Inc. She has also disclosed that she does scientific study/trial for Novartis Oncology sponsored research agreement.
Poster Discussion 5 Discussant	N/A	Michael	Press	Dr. Press has disclosed that he is a consultant/advisor for GlaxoSmithKline, Halozyme and Sanofi-Aventis. He has also disclosed that he does scientific study/trial for Dendreon. Dr. Press has disclosed that he receives grants from Genentech, Inc.
Educational Session "Treatment of Metastatic Breast Cancer - Breast Cancer as a Chronic Disease" Speaker and Moderator	Management OF ER positive	Kathleen I.	Pritchard	Dr. Pritchard has disclosed that she is a consultant/advisor for Abraxis, Pfizer, Novartis, Roche, GSK, Amgen and BI. She has also disclosed she is a meeting participant/lecturer for Abraxis, Pfizer, Novartis, Roche, GSK, Amgen and BI.

2011 SABCS Disclosure Report

Program #	Title	F. Name	L.Name	Disclosure Information
Educational Session "Reconstruction" Speaker	Measuring outcomes in breast reconstruction: The patient perspective	Andrea L.	Pusic	Dr. Pusic has no relevant financial relationships to disclose.
Committee Member	N/A	Lajos	Pusztai	Dr. Pusztai has disclosed that he is a consultant/advisor for Sanofi-Aventis. He has also disclosed that he is an employee of MD Anderson Cancer Center. Dr. Pusztai has also disclosed that he is an investigator and does scientific study/trial for AstraZeneca and Bristol-Myers Squibb.
Committee Member	N/A	Susan W.	Rafte	Ms. Rafte has no relevant financial relationships to disclose.
Special Reports Moderator/Committee Member	Special Report - Breast Cancer and the Environment: A Life Course Approach - Report Release from an IOM Committee	Amelie G.	Ramirez	Dr. Ramirez has disclosed that she is a board member/officer/trustee of Susan G. Komen for the Cure; Lance Armstrong Foundation; Avon Foundation. She has also disclosed she is an employee of University of Texas Health Science Center at San Antonio. Dr. Ramirez has disclosed that she is an investigator for NCI and Komen. She has also disclosed she is a meeting participant/lecturer for SABCS as a moderator.
Educational Session "Controversies in Early Breast Cancer" Moderator and Speaker/Committee Member	Controversies in Early Breast Cancer: Small tumors	Peter	Ravdin	Dr. Ravdin has disclosed that he is a board member/officer/trustee and owner for Adjuvant, Inc.
Committee Member	N/A	Abram	Recht	Dr. Recht has disclosed that his a consultant/advisor for Radiation Oncology Medical Advisory Board, CareCore Oncology, LLC (a benefits management company).
The Year in Review Speaker/Committee Member	Translational Breast Cancer Research	Andrea	Richardson	Dr. Richardson has disclosed that she is a consultant/advisor for Genentech.
Educational Session Moderator/Case Discussion Moderator/Committee Member	Challenges in the Care of Special Populations with Breast Cancer	Mothaffar	Rimawi	Dr. Rimawi has disclosed that he is an investigator for GSK, Genentech, Pfizer, BMS and Bipar.
The Year in Review Speaker/Committee Member	Challenges and Successes: Treatment of Metastatic Breast Cancer 2011	Hope S.	Rugo	Dr. Rugo has disclosed that she is a consultant/advisor for Genomic Health. She has also disclosed that she does scientific study/trial for Genentech/Roche, Merck, Novartis, BMS, Celgene, Sanofi/Bipar and Lilly/Imclone.
Basic Science Forum "Tumor Microenvironment" Speaker	fibrillogenesis drives metastasis in the postpartum involuting mammary gland	Pepper J.	Schedin	Dr. Schedin has no relevant financial relationships to disclose.
Mini-Symposia Moderator/Committee Member	Tumor Heterogeneity and Metastasis	Rachel	Schiff	Dr. Schiff has disclosed that she does scientific study/trials for Lilly and BMS. She has also disclosed that she did scientific study/trials for GSK and AstraZeneca.
Committee Member	N/A	Emily	Sedgwick	Dr. Sedgwick has no relevant financial relationships to disclose.
Mini-Symposia "Metabolism in Breast Cancer – Metabolomics" speaker	HIF-1, Metabolism, and Metastasis	Gregg L.	Semenza	Dr. Semenza has no relevant financial relationships to disclose.

2011 SABCS Disclosure Report

Program #	Title	F. Name	L.Name	Disclosure Information
Educational Session "What Makes a Good Target?" Moderator and Speaker	Study design considerations in the development of drugs and the diagnostic tests that can guide their use	Steve	Shak	Dr. Shak has disclosed that he is a board member/officer/trustee for Genomic Health. Dr. Shak has also disclosed that he is an employee with Genomic Health. Dr. Shak has disclosed he has an investment interest in Genomic Health.
Committee Member	N/A	Dennis	Slamon	Dr. Slamon had disclosed that he is a consultant/advisor for Novartis and GSK. He has also disclosed that he does scientific study/trial for Genentech/Roche.
Committee Member	N/A	George W.	Sledge	Dr. Sledge has no relevant financial relationships to disclose.
Basic Science Forum "Tumor Initiation" Speaker	Stem and progenitor cells and breast cancer heterogeneity	Matthew	Smalley	Dr. Smalley has no relevant financial relationships to disclose.
Plenary Speaker	Advances in Axillary Surgery: Sentinel nodes and beyond	Barbara L.	Smith	Dr. Smith has no relevant financial relationships to disclose.
Mini-Symposia "The Role and Promise of Neoadjuvant Therapy in Breast Cancer" Speaker/Committee Member	Preoperative endocrine therapy: New approaches	Ian	Smith	Dr. Smith has no relevant financial relationships to disclose.
Poster Discussion 6 Discussant	N/A	Thomas J.	Smith	Dr. Smith has no relevant financial relationships to disclose.
Committee Member	N/A	Lawrence	Solin	Dr. Solin has no relevant financial relationships to disclose.
Committee Member	N/A	Christos	Sotiriou	Dr. Sotiriou has no relevant financial relationships to disclose.
Educational Session "New Technologies for Biomarker Discovery for the Clinician" Speaker	Metabolomics as a tool to study cancer progression	Arun	Sreekumar	Dr. Sreekumar has no relevant financial relationships to disclose.
Committee Member	N/A	Sandi	Stanford	Ms. Stanford has no relevant financial relationships to disclose.
Educational Session "Treatment of Metastatic Breast Cancer – Breast Cancer as a Chronic Disease" Speaker	Triple negative breast cancer	Vered	Stearns	Dr. Stearns has disclosed that she is an investigator for initiated grants for Novartis, Pfizer, Abraxis and Merck.
Committee Member	N/A	Patricia	Steeg	Dr. Steeg has disclosed that she receives research support from GSK and Millennium.
Special Reports "Genome Data for the Masses: Presentation of TCGA and IGC Breast Tumor Data" Co-Moderator and Speaker	Diverse patterns of mutation in breast cancer genomes	Michael	Stratton	Dr. Stratton has no relevant financial relationships to disclose.
Committee Member	N/A	Saraswati	Sukumar	Dr. Sukumar has no relevant financial relationships to disclose.
Committee Member	N/A	Sandra	Swain	Dr. Swain has disclosed that she is a consultant/advisor for Novartis, Nektar, Sanofi-Aventis Pipar, Genentech/Roche (uncompensated Ad Board). She has also disclosed she is a meeting participant/lecturer for Sanofi-Aventis. Dr. Swain has disclosed she is an investigator and does scientific study/trial for Pfizer, Agendia, BMS, Genentech/Roche, Sanofi-Aventis and Bipar. She has also disclosed she travel Sanofi-Aventis for meeting above.

2011 SABCS Disclosure Report

Program #	Title	F. Name	L.Name	Disclosure Information
Committee Member	N/A	Ian	Thompson	Dr. Thompson had disclosed that he is a consultant/advisor for Ferring.
Poster Discussion 10 Discussant	N/A	Nicholas	Turner	Dr. Turner has disclosed that he is a consultant/advisor for Novartis, Roche and AstraZeneca. He has also disclosed that he receives research funding from AstraZeneca.
Committee Member/Poster Discussion 3 Discussant	N/A	Laura	van't Veer	Dr. van't Veer has disclosed she is a board member/officer/trustee and a stock owner for Agendia, Inc.
Basic Science Forum "Tumor Initiation" Speaker	p53, stem cells, and breast cancer	Geoffrey M.	Wahl	Dr. Wahl has no relevant financial relationships to disclose.
Mini-Symposia "Environmental Exposures, Epigenetics, and Epidemiology" Moderator and Speaker	Epigenetic mechanisms, endocrine disrupters, non-genomic nuclear receptors	Cheryl Lyn	Walker	Dr. Walker has no relevant financial relationships to disclose.
Basic Science Forum "Tumor Microenvironment" Speaker	Forcing breast cancer risk & progression	Valerie M.	Weaver	Dr. Weaver has no relevant financial relationships to disclose.
Educational Session Moderator/Committee Member	New Technologies for Biomarker Discovery for the Clinician	Trey	Westbrook	Dr. Westbrook has no relevant financial relationships to disclose.
Plenary Speaker/Clinical Science Forum Moderator/Committee Member	Endocrine Therapy for Breast Cancer: Looking Into The Future /Medical Economics – The Cost of Care	Eric P.	Winer	Dr. Winer has no relevant financial relationships to disclose.
Case Discussion 1 Panelist	N/A	Kay	Wissmann	Dr. Wissmann has no relevant financial relationships to disclose.
Committee Member	N/A	Antonio	Wolff	Dr. Wolff has disclosed that he is an investigator for Genentech.
Educational Session "Challenges in the Care of Special Populations with Breast Cancer" Speaker	Oncofertility: Translation in multidimensions	Teresa K.	Woodruff	Dr. Woodruff has no relevant financial relationships to disclose.
Case Discussion 1 Panelist	N/A	Wendy	Woodward	Dr. Woodward has no relevant financial relationships to disclose.
Committee Member	N/A	Douglas	Yee	Dr. Yee has no relevant financial relationships to disclose.
Committee Member	N/A	I-Tien	Yeh	Dr. Yeh has disclosed that he is a consultant/advisor for Pfizer Research.
Educational Session "Reconstruction" Speaker/Committee Member	Strange bedfellows: Radiation therapy and breast reconstruction	Richard C.	Zellars	Dr. Zellars has no relevant financial relationships to disclose.